129287-83-8

Upstream product

• 191287-33-9 (3aS,4aR,8aS,8bR)-3-((2S,3R)-2-Benzyl-3-hydroxy-butyryl)-7,7-dimethyl-hexahydro-[1,3]dioxino[4',5':4,5]furo[2,3-d]oxazol-2-one 
• 136159-65-4 (S)-4-benzyl-3-(3-phenylpropanoyl)oxazolidin-2-one 
• 501-52-0 3-Phenylpropionic acid 
• 645-45-4 hydrocinnamic acid chloride 
• 129287-76-9 (2R,5S,6R)-5-Benzyl-2-tert-butyl-6-methyl-1,3-dioxan-4-on 
• 107289-12-3 (1'RS,2R,5R,6R)-2-(tert-butyl)-5-(α-hydroxybenzyl)-6-methyl-1,3-dioxan-4-one 
• 118356-63-1 (E,2R,6R)-5-Benzyliden-2-tert-butyl-6-methyl-1,3-dioxan-4-on 

Relevant academic research and scientific papers

THERANOSTIC COMPOUNDS

This invention relates to a hydroxamate metalloprotease inhibitor compound for use in a method of diagnosing or treating cancer, inflammatory diseases or Alzheimer's disease. The compound comprises a zinc-chelating N-hydroxamate moiety radiolabeled with a radionuclide. Radiolabeled compounds of the invention may be used in targeted radionuclide therapy wherein a patient is treated with a compound of the invention comprising a diagnostic radionuclide to identify the presence of a cancer or disease, followed by treatment with a compound of the invention comprising a therapeutic radionuclide to treat said cancer or disease.

D-xylose derived oxazolidin-2-ones as chiral auxiliaries in stereoselective aldol reactions

Chiral N-acylated oxazolidin-2-one derivatives from D-xylose have been shown to undergo diastereoselective aldol reactions via their lithium imide enolates to afford β-hydroxylated products. Aliphatic substrates and aldehydes were shown to yield 'non-Evan

(E,R,R)-5-Alkylidene-2-tert-butyl-6-methyl-1,3-dioxan-4-ones: Preparation from (R)-3-Hydroxybutbutyric Acid, Cuprate Additions and Hydrolyses to 3-Hydroxycarboxylic Acids with Chiral Secondary Alkyl Substituents in the 2-Position

Li enolates of (R,R)-2-tert-Butyl-6-methyl-1,3-dioxan-4-one add to aliphatic or aromatic aldehydes with relative topicity Re,Re (2:1 to 10:1, 9 examples).The title compounds are obtained from these aldol adducts by dehydration through mesylates (5 example